Buy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising R&D Drive Growth Potential
JonesTrading analyst Catherine Novack has reiterated their bullish stance on CRNX stock, giving a Buy rating today. Catherine Novack has given her Buy rating due to a combination of factors including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback